The FAS ligand promoter polymorphism, rs763110 (-844C>T), contributes to cancer susceptibility: Evidence from 19 case-control studies

European Journal of Human Genetics

Volumn 17, Issue 10, 2009, Pages 1294-1303

  Zhang, Zhizhong ^a   Qiu, Lixin ^b   Wang, Meilin ^a   Tong, Na ^a   Li, Jin ^b   Zhang, Zhengdong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE; FAS LIGAND; THYMIDINE;

ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ETHNICITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; UTERINE CERVIX CANCER;

ALLELES; CASE-CONTROL STUDIES; FAS LIGAND PROTEIN; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MODELS, GENETIC; MODELS, STATISTICAL; NEOPLASMS; ODDS RATIO; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RISK;

EID: 70349613424     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2009.45     Document Type: Article

References (50)

1. Green DR, Droin N, Pinkoski M: Activation-induced cell death in T cells. Immunol Rev 2003; 193: 70-81.
2. Maher S, Toomey D, Condron C, Bouchier-Hayes D: Activation-induced cell death: The controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol Cell Biol 2002; 80: 131-137.
3. Chappell DB, Aestifo NP: T cell-tumor cell: a fatal interaction? Cancer Immunol Immunother 1998; 47: 65-71.
4. Ju ST, Panka DJ, Cui H et al: Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995; 373: 444-448.
5. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-1192.
6. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F: The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-1082.
7. Crnogorac-Jurcevic T, Efthimiou E, Capelli P et al: Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene 2001; 20: 7437-7446.
8. Niehans GA, Brunner T, Frizelle SP et al: Human lung carcinomas express Fas ligand. Cancer Res 1997; 57: 1007-1012.
9. Bennett MW, O'Connell J, O'Sullivan GC et al: The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998; 160: 5669-5675.
10. Houston A, O'Connell J: The Fas signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol 2004; 4: 321-326.
11. Wu J, Metz C, Xu X et al: A novel polymorphic CAAT/ enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: A candidate background gene in African American systemic lupus erythematosus patients. J Immunol 2003; 170: 132-138.
12. Zhang Z, Wang LE, Sturgis EM et al: Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 2006; 12: 5596-5602.
13. Crew KD, Gammon MD, Terry MB et al: Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis 2007; 28: 2548-2551.
14. Krippl P, Langsenlehner U, Renner W, Koppel H, Samonigg H: Re: Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 2004; 96: 1478-1479; author reply 1479.
15. Zhang B, Sun T, Xue L et al: Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 2007; 28: 1067-1073.
16. Sun T, Zhou Y, Li H et al: FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med 2005; 202: 967-974.
17. Lai HC, Lin WY, Lin YW et al: Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene-gene interaction. Gynecol Oncol 2005; 99: 113-118.
18. Kang S, Dong SM, Seo SS, Kim JW, Park SY: FAS -1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet Cytogenet 2008; 180: 1-5.
19. Ivansson EL, Gustavsson IM, Magnusson JJ et al: Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer. Int J Cancer 2007; 121: 2451-2457.
20. Li C, Wu W, Liu J et al: Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: A case-control analysis. Pharma cogenet Genomics 2006; 16: 245-251.
21. Zhang X, Miao X, Sun T et al: Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 2005; 42: 479-484.
22. Park SH, Choi JE, Kim EJ et al: Polymorphisms in the FAS and FASL genes and risk of lung cancer in a Korean population. Lung Cancer 2006; 54: 303-308.
23. Ter-Minassian M, Zhai R, Asomaning K et al: Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. Carcinogenesis 2008; 29: 2147-2152.
24. Zhang H, Sun XF, Synnerstad I, Rosdahl I: Importance of FAS-1377, FAS-670, and FASL-844 polymorphisms in tumor onset, progression, and pigment phenotypes of Swedish patients with melanoma: A case-control analysis. Cancer J 2007; 13: 233-237.
25. Li C, Larson D, Zhang Z et al: Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics 2006; 16: 253-263.
26. Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D: Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 2004; 96: 1030-1036.
27. Hsu PI, Lu PJ, Wang EM et al: Polymorphisms of death pathway genes FAS and FASL and risk of premalignant gastric lesions. Anticancer Res 2008; 28: 97-103.
28. Gormus U, Ergen A, Yilmaz H, Dalan B, Berkman S, Isbir T: Fas-1377A/G and FasL-844 T/C gene polymorphisms and epithelial ovarian cancer. Anticancer Res 2007; 27: 991-994.
29. Erdogan M, Karadeniz M, Berdeli A et al: Fas/Fas ligand gene polymorphism in patients with papillary thyroid cancer in the Turkish population. J Endocrinol Invest 2007; 30: 411-416.
30. Yang M, Sun T, Wang L et al: Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin Cancer Res 2008; 14: 3230-3236.
31. Qiu D, Kurosawa M, Lin Y et al: Overview of the epidemiology of pancreatic cancer focusing on the JACC Study. J Epidemiol 2005; 15 (Suppl 2): S157-S167.
32. Wei Q, Cheng L, Amos CI et al: Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: A molecular epidemiologic study. J Natl Cancer Inst 2000; 92: 1764-1772.
33. Cohen SM, Shirai T, Steineck G: Epidemiology and etiology of premalignant and malignant urothelial changes. Scand J Urol Nephrol Suppl 2000; 205: 105-115.
34. Blot WJ, McLaughlin JK, Winn DM et al: Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988; 48: 3282-3287.
35. Au WW, Abdou-Salama S, Sierra-Torres CH, Al-Hendy A: Environmental risk factors for prevention and molecular intervention of cervical cancer. Int J Hyg Environ Health 2007; 210: 671-678.
36. Persson I: Estrogens in the causation of breast, endometrial and ovarian cancers - evidence and hypotheses from epidemiological findings. J Steroid Biochem Mol Biol 2000; 74: 357-364.
37. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22 719-748.
38. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
39. Whitehead A, Whitehead J: A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 1991; 10 1665-1677.
40. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
41. Thakkinstian A, McElduff P, D'Este C, Duffy D, Attia J: A method for meta-analysis of molecular association studies. Stat Med 2005; 24: 1291-1306.
42. Kabelitz D, Pohl T, Pechhold K: Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes. Immunol Today 1993; 14: 338-339.
43. DeBruin LS, Josephy PD: Perspectives on the chemical etiology of breast cancer. Environ Health Perspect 2002; 110 (Suppl 1): 119-128.
44. Suzuki N, Wakisaka S, Takeba Y, Mihara S, Sakane T: Effects of cigarette smoking on Fas/Fas ligand expression of human lymphocytes. Cell Immunol 1999; 192: 48-53.
45. Elnemr A, Ohta T, Yachie A et al: Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape. Int J Oncol 2001; 18: 33-39.
46. Kelsey JL, Gammon MD: The epidemiology of breast cancer. CA Cancer J Clin 1991; 41: 146-165.
47. Song RX, Santen RJ: Apoptotic action of estrogen. Apoptosis 2003; 8: 55-60.
48. Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P: Role of exogenous and endogenous hormones in endometrial cancer: Review of the evidence and research perspectives. Ann NY Acad Sci 2001; 943: 296-315.
49. Mor G, Kohen F, Garcia-Velasco J et al: Regulation of fas ligand expression in breast cancer cells by estrogen: Functional differences between estradiol and tamoxifen. J Steroid Biochem Mol Biol 2000; 73: 185-194.
50. Dong L, Wang W, Wang F et al: Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells. J Biol Chem 1999; 274: 32099-32107.